Compare ADMA Biologics Inc (ADMA) vs Nutanix Inc (NTNX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Nutanix Inc — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while Nutanix Inc trades at $53.52 (market cap $14.53B). The key difference: Nutanix Inc is far larger — about 6.8× ADMA Biologics Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | NTNX | |
|---|---|---|
Market Cap | $2.13B | $14.53B |
Sector | Health | Technology |
52-Week High | $20.38 | $81.12 |
52-Week Low | $7.60 | $34.41 |
Enterprise Value | $2.20B | $14.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Nutanix (NTNX) trades at $52.42, up 2.22% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with Q3 2026 earnings beating expectations, 87% gross margins, and projected revenue growth to $2.7B in 2026. Recent NVIDIA certification for Unified Storage and expanding enterprise partnerships highlight strategic positioning in hybrid cloud infrastructure.
Outlook remains positive with 62.5% analyst buy ratings and $56.55 consensus target, though elevated P/E ratio of 55.17 and RSI near overbought levels suggest near-term consolidation risk. Key catalysts include AI infrastructure adoption and VMware migration opportunities, while execution risks and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
